Combining the KINOMEscan‐LINCS biochemical kinase profiling database with the ChEMBL database of targets associated with SARS‐CoV, our colleagues identified gilteritinib,12 an approved drug for treatment of relapsed/refractory acute myeloid leukemia (AML); as an AXL inhibitor, the agent shows robust activity against different subvariants of concern in SARS‐CoV‐2 infection models. Here, AXL is linked to acute myeloid leukemia.